Ubs Group Ag Humacyte, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Humacyte, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 123,803 shares of HUMA stock, worth $690,820. This represents 0.0% of its overall portfolio holdings.

Number of Shares

123,803

Previous 94,185 31.45%

Holding current value

$690,820

Previous $292,000 103.42%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.87 - $9.1 $85,003 - $269,523	29,618 Added 31.45%	123,803 $594,000
Q1 2024 May 13, 2024	BUY	$2.57 - $4.84 $23,723 - $44,678	9,231 Added 10.87%	94,185 $292,000
Q4 2023 Feb 09, 2024	BUY	$1.99 - $3.12 $102,560 - $160,798	51,538 Added 154.23%	84,954 $241,000
Q3 2023 Nov 09, 2023	BUY	$2.75 - $4.48 $1,190 - $1,939	433 Added 1.31%	33,416 $97,000
Q2 2023 Aug 11, 2023	BUY	$2.86 - $4.97 $35,461 - $61,623	12,399 Added 60.24%	32,983 $94,000
Q1 2023 May 12, 2023	BUY	$2.11 - $3.25 $36,861 - $56,777	17,470 Added 561.01%	20,584 $63,000
Q4 2022 Feb 08, 2023	SELL	$2.02 - $3.62 $13,560 - $24,301	-6,713 Reduced 68.31%	3,114 $6,000
Q3 2022 Nov 10, 2022	BUY	$1.22 - $5.14 $5,746 - $24,209	4,710 Added 92.05%	9,827 $32,000
Q2 2022 Aug 10, 2022	BUY	$3.21 - $7.86 $16,425 - $40,219	5,117 New	5,117 $16,000
Q1 2022 May 16, 2022	SELL	$4.65 - $7.4 $1.12 Million - $1.79 Million	-241,374 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.25 - $11.6 $1.74 Million - $2.79 Million	240,596 Added 30924.94%	241,374 $1.75 Million
Q3 2021 Nov 15, 2021	BUY	$9.21 - $16.99 $7,165 - $13,218	778 New	778 $9,000

Others Institutions Holding HUMA

# of Institutions

130

Shares Held

30.8M

Call Options Held

323K

Put Options Held

582K

View Full List

About Humacyte, Inc.

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $575M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

More about HUMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account